natgillin/translations-raw huggingface dataset:
In order to further improve the functionality of the sugar replacement composition, insoluble, non selective, non digestible polysaccharides may be added to the sugar replacement composition according to the second and third embodiments of the invention, as represented in tables 11 and 12. 
Da bi se još više poboljšala funkcionalnost sastavine koja zamjenjuje šećer, mogu joj se dodati netopljivi, neselektivni, neprobavljivi polisaharidi, u skladu s drugom 1 trećom varijantom koje su prikazane u tablicama 111 12.
Because the aerosol forming substance is physically separate from the fuel element, it is exposed to substantially lower temperatures than are present in the burning fire cone. 
Zato što je supstanca za formiranje aerosola fizički odvojena od gorivog elementa, izložena je suštinski nižim temperaturama nego što su prisutne u gorivom plamenom konusu.
3 shows the solid-state fluorine-19 MAS NMR spectrum for the crystalline monohydrate form of the dihydrogenphosphate salt of structural formula II. 
SL. 3 prikazuje kruti fluorin-19 MAS NMR spektar za kristalni monohidratni oblik dihidrogenfosfatne soli strukturne formule II.
Embodiment 3. The pharmaceutical composition of embodiment 1 wherein the crosslinked amine polymer has an equilibrium chloride binding capacity of at least 7.5 mmol/g in an aqueous simulated gastric fluid buffer ("SGF") containing 35 mM NaCl and 63 mM HCI at pH 1.2 and 37 °C. 
Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-3, gdje je umreženi aminski polimer sa ravnotežnim kapacitetom vezanja klorida od najmanje 7,5 mmol/g u vodenom puferu simulirane želučane tekućine ("SGF") koji sadrži 35 mM NaCI 1 63 mM FCI, pH 1,21 na 37%.
An irrelevant antibody was included as a negative control. 
Kao negativna kontrola uključena je irelevantno protutijelo.
118. Even more preferred, the V regions of the second binding domain specific for CEA of the bispecific single chain antibodies defined herein are selected from the group consisting of: 
Farmaceutski pripravak u skladu s bilo koji od patentnih zahtjeva 1 do 8, naznačen time što se V područja u drugoj vežućoj domeni specifičnoj za CEA bira iz skupine koju čine:
The process of producing a compound of formula VIII or a pharmaceutically acceptable salt thereof comprising the steps of reacting a compound of formula VII or an acid addition salt thereof wherein R1 is -(CO)NH2, -CH2NH2 or -CN; 
Postupak za dobivanje spoja sa formulom VIII (VIII) ili njegove farmaceutski prihvatljive soli naznačen time da sadrži slijedeće korake: a) reakciju spoja sa formulom VII ili njegove kisele adicijske soli OH oo pri čemu R, je (CO)NH>,, -CH2NAH, ili -CN;
The liquid pharmaceutical composition according to claim 1, which comprises said one or more cosolvents in a total amount of from 45% to 85% (w/v). 
Farmaceutski sastav prema zahtjevu 3, naznačen time, da on sadrži ukupnu količinu spomenutih ko-otapala u rasponu od 30% do 85% (masa/volumen).
encoding at least one isolated IL-23p19 antibody according to any of claims 1-4; or comprising at least one of: 
kodira najmanje jedno izolirano IL-23p19 antitijelo prema patentnom zahtjevu 1 ili patentnom zahtjevu 2;(b) sadrži najmanje jednu od:
An IL-17 binding antibody or fragment thereof according to any of the preceding claims, which comprises at least one antigen binding site comprising either 
IL-17-vezivno protutijelo ili njegov fragment, za uporabu prema zahtjevu 1 ili zahtjevu 2, naznačeno time, da sadrži najmanje jedno mjesto za vezanje antigena, koje obuhvaća sljedeće:
stands for hydrogen atom or for methyl group; stands for hydrogen atom or for methyl group; stands for a phenyl- or thienyl-, or furyl group, optionally substituted with one or more, identical or different, straight or branched C1-4 alkyl group, straight or branched C1-4 alkoxy group, or halogen atom, or 
predstavlja atom vodika ili metilnu skupinu; predstavlja atom vodika ili metilnu skupinu; predstavlja fenilnu ili tienilnu ili furilnu skupinu, izborno supstituiranu s jednom ili više, istovjetnih ili različitih, nerazgranatih ili razgranatih C1-4 alkilnih skupina, nerazgranatih ili razgranatih C1-4 alkoksi skupina ili atoma halogena, ili
Urinary as well as recombinant IL-18BP specifically bind IL-18 with a high affinity and modulate the biological affinity of IL-18. 
IL-18BP iz urina, kao i rekombinantni IL-18BP, specifično i visoko afinitetno veže IL-18 te modulira biološki afinitet IL-18.
A bulwark terrace assembly for a boat having a hull, a deck and a bulwark extending upwards from the deck and along a longitudinal side of the boat hull, the bulwark terrace assembly comprising: 
Brod koji ima trup, palubu i linicu koja se proteže prema gore od palube i uzdužnu stranu trupa broda, pri čemu brod sadrži:
The compound according to claim 1 wherein R-A is selected from 
Spoj prema patentnom zahtjevu 1 naznačen time što R-A je izabran od [image] [image] ili [image]
The compound or salt according to claim 1, wherein Ar is a phenyl group, a pyridyl group, a thienyl group, or a furyl group. 
Spoj ili sol prema zahtjevu 1 ili 2, naznačen time, da je Ar fenilna skupina, piridilna skupina, tienilna skupina, ili furil skupina.
contacting a biological sample of the subject with at least one anti-human p53 antibody according to any of claims 1 to 2 under conditions suitable for the formation of an immunocomplex between the human p53 protein and the at least one antibody; and detecting the formation of an immunocomplex between the human p53 protein and the at least one antibody, the formation of the immunocomplex being indicative of Alzheimer's disease. 
(1) < kontaktiranje biološkog uzorka subjekta s barem jednim anti-humanim p53 antitijelom prema bilo kojem od zahtjeva 1 do 2 pod uvjetima povoljnim za stvaranje imunokompleksa između humanog p53 proteina i barem jednog antitijela; 1 (ii) otkrivanje stvaranja imunokompleksa između humanog p53 protema i barem jednog antitijela, gdje je stvaranje imunokompleksa indikativno za Alzheimerovu bolest.
A pharmaceutical composition as in clause 2, wherein the increase in residence time of rifaximin formulation in the gastrointestinal tract is achieved by bioadhesion. 
Oralni farmaceutski pripravak s kontroliranim oslobađanjem prema zahtjevu 2, naznačen time da se produljenje vremena zadržavanja rifaksimina u probavnom sustavu postiže bioadhezijom.
the compound cyprodinil. 
(B) spoj fluopiram.
Use of a compound according to claim 1 for the preparation of a medicament for inhibiting tumor/cancer growth in a subject. 
Uporaba formule sukladno patentnom zahtjevu 1, radi pripreme medikamenta za spriječavanje proliferacije stanica tumora/raka kod pojedinca.
The set of polypeptides according to claim 14, wherein said functional domain F is a Fv (variant fragment) or a scFv (single-chain variant fragment) of an antibody. 
Skup polipeptida u skladu s patentnim zahtjevom 14, naznačen time što je navedena funkcionalna domena F Fv (varijantni fragment) ili scFv (jednolančani varijantni fragment) protutijela.
The combination for use of claim 12, wherein the therapeutic agent is: an antibiotic, polyclonal gamma-globulin, probiotic agent or C . difficile vaccine; or 
Antitijelo, ili njegov dio koji se veže za antigen, prema patentnom zahtjevu 20, naznačeno time što je terapeutsko sredstvo antibiotik, poliklonalni gama-globulin, probiotsko sredstvo ili C. difficile vakcina.
increasing the temperature of the frozen G-CSF composition of step (c) to a temperature within the range of from 2°C to 8°C over a period of time adjusted to allow the composition to thaw and to obtain a liquid composition having a G-CSF content of at least 95% of the G-CSF content of the composition provided in step (a). 
(d) povećanje temperature zamrznutog G-CSF-sastava iz koraka (c) na temperaturu u rasponu od 2%C do 8"C u vremenskom periodu namještenom tako da dopusti sastavu odmrzavanje te za dobivanje tekućeg sastava koji ima sadržaj G-CSF od najmanje 95% sadržaja sastava pribavljenog u koraku (a).
A method according to either one of claims 1 or 2, wherein the third channel is a mobile phone network (170) and the step of retrieving the personal identification number includes a step of checking the user mobile phone number (205). 
korak slanja korisniku dohvaćenog osobnog koda (210) putem trećeg kanala, pri čemu su drugi kanal i treći kanal pokretna telefonska mreža (170), te pri čemu je drugi kanal mreža za prijenos kratkih poruka, a pri čemu korak prijema osobnog koda uključuje korak provjere mobilnog telefonskog broja (205) korisnika u drugom kanalu.
The method according to any one of claims 29 and 30 wherein the reducing agent is selected from the group consisting of sodium cyanoborohydride (NaCNBH3), ascorbic acid (vitamin C) and NaBH3. 
Postupak prema bilo kojem od zahtjeva 29 i 30, pri čemu je reducirajući agens odabran od skupine koja se sastoji 35 od natrij cijanoborohidrida (NaCNBH>), askorbinske kiseline (vitamin €) i NaBH:.
The process of claim 6, wherein the dosage form is subjected to a temperature of at least about 60 °C or at least about 62 °C, preferably at least about 68 °C, at least about 70 °C, at least about 72 °C or at least about 75 °C or from about 62 °C to about 85 °C for a time period of at least about 15 minutes, at least about 30 minutes, at least about 60 minutes or at least about 90 minutes. 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 1 ili 2, naznačen time da, formulacija matrice s produljenim otpuštanjem ima snagu pucanja od barem oko 120 N, od barem oko 130 N ili od barem oko 140 N i/ili „dubinu prodiranja s razmakom pukotine“ od barem oko 1.2 mm, poželjno od barem oko 1.4 mm, od barem oko 1.5 mm ili od barem oko 1.6 mm.
A drug-delivery device comprising: a body comprising a matrix of a silicone and an ophthalmic drug, the body having an outer surface and being configured to be inserted through a punctal aperture and positioned in a punctum or lacrimal canaliculus; 
(a) tijelo, koje sadrži silikonski matriks i oftalmički lijek, gdje tijelo ima vanjsku površinu i tako je oblikovano da se može umetnuti kroz punktalni otvor i staviti u punktum (ulaz u suzni kanalić) ili suzni kanalić;
The liquefied gas treatment system according to claim 1, further comprising a forcible vaporizer configured to forcibly vaporize the LNG stored in the cargo tank and supply the forcibly vaporized LNG to the compressor. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 7, naznačen time što se treću struju dodatno komprimira u drugom kompresoru (13b) i šalje u izmjenjivač topline (21).
said EDTA, present in an amount of 0.125 mg, said composition being reconstituted with 2 ml of water for injection, wherein total amount of sodium content of said ceftriaxone sodium and said sulbactam sodium is 16.535 mg with 0.717 mEq of sodium. 
(c) spomenuti EDTA prisutan u količini od 0.125 mg, spomenuta smjesa je rekonstituirana sa 2 ml vode za injekcije, i gdje ukupna količina natrija sadržanog u spomenutom ceftriakson natriju i spomenutom sulbaktam natriju iznosi 16.535 mg, uz 0.717 mEq natrija.
a method of treating or preventing a disorder associated with aberrant Stat3 pathway activity in a subject, the method comprising administering to the subject a therapeutically effective amount of the first agent and the one or more second agents, such that at least aberrant Stat3 pathway activity is reduced; a method of treating a subject, the method comprising the steps of identifying a subject by aberrant Stat3 pathway activity and administering to the subject a therapeutically effective amount of the first agent and the one or more second agents; 
liječenju raka u bolesnika za kojeg je ispitano da ima rak koji pokazuje neprirodnu aktivnost signalnog puta Stat3 preko primjene terapijski učinkovite količine spoja formule VIII bolesniku; liječenju raka u subjekta inhibicijom preživljavanja matičnih stanica raka i/ili samo-obnove, koje obuhvaća primjenu učinkovite količine spoja formule VIII na matične stanice raka;
is piperidinyl substituted with 1 substituent selected from the group consisting of 
R* je piperidinil supstituiran sa 1 supstituentom izabranim iz grupe koju čine
The pharmaceutical composition of claim 18 for use in treating a malignant tumor in an animal; and optionally wherein said animal is human. The pharmaceutical composition for use according to claim 20, wherein said malignant tumor is selected from the group consisting of: melanoma, non-small cell lung cancer, hepatocellular carcinoma, gastric cancer, bladder cancer, lung cancer, renal cell carcinoma, cervical cancer, colon cancer, colorectal cancer, head and neck cancer, breast cancer, oesophageal cancer, bone cancer, prostate cancer, basal cell carcinoma, biliary tract cancer, brain and CNS cancer, choriocarcinoma, connective tissue cancer, cancer of the digestive system, endometrial cancer, eye cancer, intra-epithelial cancer, kidney cancer, larynx cancer, leukaemia, liver cancer, lung cancer, lymphoma, myeloma, neuroblastoma, oral cavity cancer, ovarian cancer, rhabdomyosarcoma, sarcoma, skin cancer, testicular cancer, thyroid cancer, uterine cancer, urinary tract cancer, and pancreatic cancer. 
Protutijelo ili njegov fragment za vezanje, za uporabu u skladu s patentnim zahtjevom 10, ili farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 10, naznačen/o time, da je navedeni maligni tumor odabran iz skupine koja se sastoji od sljedećih: melanom, rak ne-malih stanica pluća, hepatocelularni karcinom, rak želuca, rak mokraćnog mjehura, rak pluća, karcinom renalnih stanica, rak cerviksa, rak debelog crijeva, kolorektalni rak, rak glave i vrata, rak dojke, rak jednjaka, rak kostiju, rak prostate, karcinom bazalnih stanica, rak žučnog trakta, rak mozga i centralnog nervnog sustava, koriokarcinom, rak vezivnog tkiva, rak digestivnog trakta, endometrijski rak, rak oka, intraepitelni rak, rak bubrega, rak grla, leukemija, rak jetre, limfom, mijelom, neuroblastom, rak oralne šupljine, rak jajnika, rabdomiosarkom, sarkom, rak kože, rak testisa, rak tiroidne žlijezde, rak maternice, rak urinarnog trakta i rak gušterače.
a rectangular frame comprised of the at least four frame-members (H 1, H 2, H 3, H 4); and 
(1) pravokutnog okvira sastavljenog od najmanje četiri okvirna elementa (H,, H>, H,,
reacting the thus obtained compound of general formula (I), wherein R has the above defined meaning, with ethyl magnesium halide in an inert reaction medium under Grignard conditions, 
reagiranje tako dobivenog spoja opće formule (I), [image] pri čemu R ima gore definirano značenje, sa etil magnezij halidom u inertnom reakcijskom mediju pri Grignardovim uvjetima,
The anti-sclerostin antibody for use according to any one of claims 1-11, wherein an anti-resorptive is administered to the human following the treatment period, optionally a treatment period of 12 months. 
Antisklerostinsko antitijelo za primjenu prema bilo kojem zahtjevu od 1 do 11, naznačeno time, što se antiresorpcijsko sredstvo primjenjuje kod osobe nakon razdoblja liječenja, opcionalno nakon razdoblja liječenja od 12 mjeseci.
one of Rc and Rd is selected from hydrogen, substituted or unsubstituted lower alkyl and hydroxy, while the other one of Rc and Rd is a 3-7 member, preferably a 5 or 6 member cyclic moiety, preferably a cyclic carbohydrate moiety, wherein the cyclic moiety is unsubstituted or substituted, preferably substituted by at least one functional group suitable for conjugation of a polymeric moiety, more preferably substituted in at least one, preferably 2 to 3 and up to all positions of the cycle by hydroxy, substituted or unsubstituted lower alkyl, lower alkoxy, carboxy, alkoxycarbonyl, amino, lower alkylamino, lower alkylaminocarbonyl or oxime group; or 
(a) nezavisno vodik ili organski ostatak izabran iz grupe koju čine supstituirani ili nesupstituirani niži alkil, supstituirani ili nesupstituirani niži alkenil, supstituirani ili nesupstituirani niži alkinil, hidroksi, niži alkoksi, karboksi ili alkoksikarbonil; ili jedan od R" i R" je izabran od vodika, supstituiranog ili nesupstituiranog nižeg alkila i hidroksi, dok, drugi od R"i R" je 3-7 -člana ciklična grupa, pri čemu je ciklična grupa nesupstituirana ili supstituirana, sa najmanje jednom funkcionalnom grupom pogodnom za konjugaciju polimerne grupe, ili
providing waterproof layers on the interior walls and floor of said compartment for creating a wet area within said module, 
(ili) stvarajući mokro područje unutar navedenog modula (2) pružanjem vodootpornih slojeva s unutarnjih strana zidova i poda navedenog odjeljka,
The incorporation of lipophilic ancillary groups within the structure of the linker to enhance the lipophilicity and/or hydrophobicity of the rapamycin carbohydrate derivatives is also within the scope of this invention. 
Ugradnja lipofilnih pomoćnih grupa u strukturu veznika kako bi se povećala lipofilnost i/ili hidrofobnost ugljikohidratnog derivata rapamicina također je u opsegu ovog izuma.
In the preferred embodiment wherein the agent is an antibody directed against an extra-cellular part of the receptor, the antibody is preferably directed against a peptide comprising a sequence corresponding to the binding motif of the Vps10p domain, said motif comprising SEQ ID NO: 25, 26, 27 or 28 or a fragment or variant hereof. 
Protutijelo usmjereno prema izvanstaničnom dijelu Sortilina koje je sposobno inhibirati vezanje pro-neurotrofina za vezno mjesto receptora Sortilina, pri čemu se protutijelo veže za motiv vezanja za pro-neurotrofin u skladu sa SEQ ID NO:25, 26, 27 ili 28 ili za njegov fragment.
Preferably, the heat exchange relationship between the fuel element and the aerosol generating means is achieved by providing a heat transferring member, preferably a heat conducting member, such as a metal foil, which efficiently transfers or conducts heat from the burning fuel element to the aerosol generating means. 
Pogodno, sredstvo za generiranje aerosola uključuje jednu ili više supstanci za formiranje aerosola, Poželjno, odnos za toplinsku razmjenu između goriva i generatora aerosola postiže se osiguravanjem člana koji provodi toplinu, kao što je metalna folija, koja efikasno provodi ili prenosi toplinu sa izgorivog gorivog elementa na sredstvo za generiranje aerosola.
The method of claim 3, wherein Pr is benzyl and is removed using zinc and acetyl chloride. 
Postupak prema zahtjevu 10, gdje Pr je benzil i uklanja se pomoću cinka i acetil klorida.
The components of the nitrite layer are: 
Datum objave europskog patenta:
The immunoconjugate of claim 4, wherein the IgG1 molecule comprises in its Fc domain one or more amino acid mutations that reduce the binding affinity of the immunoconjugate to an FcYRIIIa, FcYRI or FcYRIIa receptor. 
Imunokonjugat iz bilo kojeg od patentnih zahtjeva 1 do 4, naznačen time, da navedena Fc domena obuhvaća jednu ili više mutacija aminokiselina, koja(e) smanjuje(u) vezanje Fc domene na Fc receptor, naročito FcY receptor.
It is self-evident that different veneer types (different species of wood, patterns from wood and other materials, colored or dyed adhesives) can be produced and can be converted according to customers' requirements. 
Samo po sebi je jasno da različite vrste furnira (različite vrste drva, različiti uzorci od drva i od drugih materijala, obojena ljepila ili ljepila u boji) mogu biti proizvedene i mogu biti dovršene u skladu sa zahtjevima korisnika.
The compound of claim 2, wherein R1 is a hydrogen atom, a halogen atom or an alkyl group having a carbon number of 1 to 6; 
Spoj prema zahtjevu 2, naznačen time, da R' je atom vodika, atom halogena ili alkilna skupina koja ima broj ugljika od 1 do 6;
detecting the formation of or determining the amount of a complex between the agent and the nucleic acid or the part thereof, the tumor-associated antigen or the part thereof, the antibody or the T lymphocytes. 
detekciju formiranja ili određivanje količine kompleksa između sredstva i nukleinske kiseline ili antigena koji je povezan sa tumorom.
The peptide of the first aspect of the invention consists of the sequence EDNIMVTFRNQASR. 
(32) Datum podnošenja prve prijave: 18.05.2009.
The weight content of other constituents in the composite material is typically in the range of 0-10%, such as 0-5%, e.g. 
Maseni udio drugih sastojaka kompozitnog materijala je tipično u rasponu od 0-10% kao što je 0-5%, npr.
The composition according to claim 1, in a dry form selected from the group consisting of powder, granules, and flakes. 
Sastav usklađen s patentnim zahtjevom 1 u suhom obliku odabranom između praha, granula, pahuljica.
TriVA DiVA-242 A composition comprising the compound of claim 1-4. 
Pripravak koji se sastoji od spoja u skladu s patentnim zahtjevima 1-4.
The assembly according to claim 1, wherein said housing comprises a plurality of accommodations, and each of said accommodations is configured to accommodate at least one scent module. 
Sklop u skladu sa bilo kojim ili više od jednog od prethodnih patentnih zahtjeva, gdje navedeno kućište sadrži više prijemnih dijelova, i svaki od navedenih prijemnih dijelova je konfiguriran da primi najmanje jedan mirisni modul.
For example, phosphate, citrate, and carbonate buffers may be included, but the preferred buffer for use according to the invention is a phosphate buffer system. 
Na primjer, mogu biti uključeni fosfatni, citratni i karbonatni puferi, ali poželjni pufer za primjenu prema izumu je fosfatni puferski sustav.
The process according to claim 25 wherein said solvent is an aprotic solvent. 
Postupak prema patentnom zahtjevu 25 gdje navedeno otapalo jest aprotonsko otapalo.
is phenyl or a 5- to 6-membered heteroaryl group containing 1 to 3 heteroatoms independently chosen from N, O, and S, where each J1 is optionally substituted with one or more substituents independently chosen from amino, cyano, hydroxyl, halogen, C1-C4alkyl, C1-C4alkoxy, mono- and di- C1-C4alkylamino, C1-C2haloalkyl, and C1-C2haloalkoxy; 
je fenil ili 5- do 6-člana heteroaril grupa koja sadrži 1 do 3 heteroatoma neovisno izabrana iz N, O, i S, pri čemu je svaki J1 opcionalno supstituiran s jednim ili više supstituenata neovisno izabranih iz amino, cijano, hidroksil, halogen, C1-C4alkil, C1-C4alkoksi, mono- i di- C1-C4alkilamino, C1-C2haloalkil, i C1-C2haloalkoksi;
A lyophilized powder obtainable by lyophilization of the pharmaceutical composition of any of the preceding claims and being suitable for reconstitution to form a liquid composition for parenteral, preferably intravenous, administration. 
Liofilizirani prašak, naznačen time, da se dobiva liofilizacijom farmaceutskog sastava prema bilo kojem od prethodnih zahtjeva, te da je pogodan za preoblikovanje, u svrhu tvorbe tekućeg sastava za parenteralnu, poželjno intravenoznu primjenu.
The use of the system according to claim 1, wherein the second composition of the second component of the system further comprises at least one preservative agent. The use of the system according to any of the claims 1-8, wherein the at least one enzyme-activating agent of the second composition of the second component of the system constitutes 95 percent by weight of the second component. 
Upotreba sustava u skladu sa zahtjevom 1, naznačena time, što se drugi sastav od druge komponente sustava nadalje sastoji od najmanje jednog sredstva zaštite. . Upotreba sustava u skladu sa bilo kojim zahtjevom 1-8, naznačena time, što barem jedno sredstvo aktiviranja enzima drugog sastava od druge komponente sustava čini 95 posto po masi druge komponente,
A compound according to any one of claims 1-10, or a pharmaceutically acceptable salt thereof, for use in the preparation of a medicament for the prophylaxis or treatment of infection by HIV or for the prophylaxis, treatment, or delay in the onset of AIDS in a subject in need thereof. 
Uporaba farmaceutskog pripravka prema bilo kojem od patentnih zahtjeva 1-6 za proizvodnju lijeka za profilaksu ili liječenje infekcije HIV-om ili za profilaksu, liječenje ili odgađanje početka SIDA-e kod subjekta kod kojeg postoji potreba za istim.
Prepare the solution of nebivolol hydrochloride and hydroxypropyl methylcellulose or povidone in methanol or a suitable solvent and water. 
Pripremite otopinu nebivolola ili njegove farmaceutski prihvatljive soli i hidroksipropil metilceluloze ili povidona u metanolu ili odgovarajućem otapalu i vodi.